PCSK9 ELISA Kit (Human)
Referencia OKAG00244
embalaje : 1plate
Marca : Aviva Systems Biology
PCSK9 ELISA Kit (Human) : 96 Wells (OKAG00244)
| Datasheets/Manuals | Printable datasheet for PCSK9 ELISA Kit (Human) : 96 Wells (OKAG00244) |
|---|
| Predicted Species Reactivity | Homo sapiens|Human | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Format | 1 x 96-Well Plate or 12 x 8-Well Strips | ||||||||||||||||||||||
| Application | ELISA-Sandwich | ||||||||||||||||||||||
| ELISA Kit Detection Method | Colorimetric 450 nm | ||||||||||||||||||||||
| ELISA Kit Duration | 4.5 hours | ||||||||||||||||||||||
| ELISA Kit Principle | The Aviva Human PCSK9 ELISA Kit contains the components necessary for quantitative determination of natural or recombinant hPCSK9 concentrations within any experimental sample including cell lysates, serum and plasma. This particular immunoassay utilizes the quantitative technique of a "Sandwich" Enzyme-Linked Immunosorbent Assay (ELISA) where the target protein (antigen) is bound in a "sandwich" format by the primary capture antibodies coated to each well-bottom and the secondary detection antibodies added subsequently by the investigator. The capture antibodies coated to the bottom of each well are specific for a particular epitope on the Human PCSK9 cytokine while the user-added detection antibodies bind to epitopes on the captured target protein. Amid each step of the procedure, a series of wash steps must be performed to ensure the elimination of non-specific binding between proteins to other proteins or to the solid phase. After incubation and "sandwiching" of the target antigen, a peroxidase enzyme is conjugated to the constant heavy chain of the secondary antibody (either covalently or via Avidin/Streptavidin-Biotin interactions), allowing for a colorimetric reaction to ensue upon substrate addition. When the substrate TMB (3, 3’, 5, 5’-Tetramethylbenzidine) is added, the reaction catalyzed by peroxidase yields a blue color that is representative of the antigen concentration. Upon sufficient color development, the reaction can be terminated through addition of Stop Solution (2 N Sulfuric Acid) where the color of the solution will turn yellow. The absorbance of each well can then be read by a spectrophotometer, allowing for generation of a standard curve and subsequent determination of protein concentration. | ||||||||||||||||||||||
| ELISA Kit Range | 125-8000 pg/mL | ||||||||||||||||||||||
| ELISA Kit Component |
| ||||||||||||||||||||||
| Reconstitution and Storage | 2°C to 8°C | ||||||||||||||||||||||
| Sample Type | Cell lysates, sera and plasma | ||||||||||||||||||||||
| Sensitivity | 125 pg/mL | ||||||||||||||||||||||
| Specificity | The Human PCSK9 ELISA is capable of recognizing both recombinant and naturally produced Human PCSK9 proteins. The antigens listed below were tested at 50 ng/ml and did not exhibit significant cross reactivity or interference. • Human: Furin, LDL R, Proprotein Convertase 1, Proprotein Convertase 7 • Murine: Proprotein Convertase 9 | ||||||||||||||||||||||
| Assay Info | Quantitative Colorimentric Sandwich ELISA |
| Gene Symbol | PCSK9 |
|---|---|
| Gene Full Name | proprotein convertase subtilisin/kexin type 9 |
| Alias Symbols | convertase subtilisin/kexin type 9 preproprotein, FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, neural apoptosis regulated convertase 1, Neural apoptosis-regulated convertase 1, PC9, Proprotein convertase 9, proprotein convertase subtilisin/kexin type 9, subtilisin/kexin-like protease PC9. |
| NCBI Gene Id | 255738 |
| Protein Name | Proprotein convertase subtilisin/kexin type 9 |
| Description of Target | Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. |
| Uniprot ID | Q8NBP7 |
| Protein Accession # | NP_777596.2 |
| Nucleotide Accession # | NM_174936.3 |
